IDO1抑制剂epacadostat对比他莫昔芬治疗仅生化复发(CA-125升高)上皮性卵巢癌、原发腹膜癌或输卵管癌的随机开放标签2期研究
这项开放标签2期研究将仅CA-125升高的生化复发卵巢癌、原发腹膜癌或输卵管癌患者按1:1随机分配至epacadostat 600mg或他莫昔芬20mg每日两次口服。主要终点为研究者评估的无进展生存期(PFS),epacadostat组中位PFS 3.75个月对比他莫昔芬组5.56个月(HR 1.34,95%CI 0.58-3.14,P=0.54),两组无显著差异。研究因入组缓慢和缺乏优效性证据而终止,epacadostat总体耐受性良好。
要点
- 仅CA-125升高的生化复发卵巢癌患者中,epacadostat组中位PFS 3.75个月对比他莫昔芬组5.56个月,HR 1.34(95%CI 0.58-3.14),P=0.54。
- 可评估患者中,epacadostat组1例(5.0%)和他莫昔芬组3例(15.8%)达到确认的CA-125缓解。
- epacadostat组最常见的免疫相关不良事件为皮疹(18.2%)和瘙痒(9.1%),总体耐受性良好。
核心结论
- 这是首项在仅生化复发卵巢癌中评估免疫治疗以及首项在卵巢癌中评估IDO1抑制剂单药治疗的报告,发现epacadostat与他莫昔芬之间疗效无显著差异。
- epacadostat总体耐受性良好。
研究设计与样本
- 开放标签、随机、2期研究(NCT01685255),患者按1:1随机分配至epacadostat 600mg或他莫昔芬20mg每日两次口服,连续28天为一周期。
- 按一线化疗结束至首次CA-125升高时间(3至<12个月或≥12个月)分层。
- 主要终点为研究者评估的无进展生存期(PFS;RECIST v1.1)。
- 次要终点包括CA-125缓解(妇科肿瘤协作组标准)、总生存期、安全性和耐受性。
主要发现
- epacadostat组(n=22)中位PFS为3.75个月,他莫昔芬组(n=20)为5.56个月(HR 1.34,95%CI 0.58-3.14;P=0.54)。
- 可评估患者中,epacadostat组1例(5.0%)和他莫昔芬组3例(15.8%)达到确认的CA-125缓解。
- 最常见的治疗中出现的不良事件为乏力(epacadostat组36.4%;他莫昔芬组40.0%)。
- 仅epacadostat组观察到免疫相关不良事件,主要为皮疹(18.2%)和瘙痒(9.1%)。
- 94%的存档肿瘤样本中观察到IDO1表达。
局限性
- 研究主要因入组缓慢和缺乏优效性证据而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat versus tamoxifen in patients with biochemical-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. METHODS: In this open-label, phase 2 study (NCT01685255), patients were randomised 1:1 to epacadostat 600mg or tamoxifen 20mg twice daily for successive 28-day cycles and stratified by time since completion of first-line chemotherapy to first CA-125 elevation (3 to <12 or ≥12months). The primary endpoint was investigator-assessed progression-free survival (PFS; RECIST v1.1). Secondary endpoints included CA-125 response (Gynecologic Cancer InterGroup criteria), overall survival, safety, and tolerability. RESULTS: The study was terminated primarily due to slow accrual and lack of evidence of superiority. Median PFS was 3.75months for epacadostat (n=22) versus 5.56months for tamoxifen (n=20; HR, 1.34 [95% CI, 0.58-3.14]; P=0.54). Of evaluable patients, 1 (5.0%) epacadostat and 3 (15.8%) tamoxifen patients had confirmed CA-125 responses. The most common treatment-emergent adverse event was fatigue (epacadostat, 36.4%; tamoxifen, 40.0%). Immune-related adverse events, observed with epacadostat only, were primarily rash (18.2%) and pruritus (9.1%). Epacadostat pharmacokinetics/pharmacodynamics were consistent with its known mechanism of action. IDO1 expression was observed in 94% of archival tumour samples. CONCLUSIONS: This first report of immunotherapy evaluation in biochemical-only relapse ovarian cancer and of IDO1 inhibitor monotherapy in ovarian cancer found no significant difference in efficacy between epacadostat and tamoxifen. Epacadostat was generally well tolerated.
引用
- Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol. 2017. PMID: 28698009. doi:10.1016/j.ygyno.2017.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。